791758-82-2

Usage

Uses

Used in Pharmaceutical Applications:
(S)-1-(Tetrahydro-2H-pyran-4-yl)pyrrolidin-3-aMine is used as a potential drug candidate for the treatment of various medical conditions due to its unique chemical structure and properties. Its versatility in organic synthesis allows for the development of new therapeutic agents that can target a wide range of health issues.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-1-(Tetrahydro-2H-pyran-4-yl)pyrrolidin-3-aMine serves as a valuable building block for the creation of diverse organic compounds. Its structural features enable chemists to design and synthesize novel molecules with specific functionalities and applications, contributing to the advancement of chemical research and development.
Used in Drug Development:
(S)-1-(Tetrahydro-2H-pyran-4-yl)pyrrolidin-3-aMine's potential pharmaceutical applications make it an essential component in drug development. (S)-1-(Tetrahydro-2H-pyran-4-yl)pyrrolidin-3-aMine can be employed in the design and synthesis of new drugs, targeting various medical conditions and improving the efficacy and safety of existing treatments.

Upstream product

• 877661-68-2 (S)-tert-butyl 1-(tetrahydro-2H-pyran-4-yl)pyrrolidin-3-ylcarbamate 

Relevant academic research and scientific papers

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Pteridinone derivatives as PI3-kinases inhibitors

New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.

New pteridinones as PLK inhibitors

Disclosed compounds of general formula (1) wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3 and R4 are defined as in claim 1, which are suitable for the trea